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ContinuedSUMMARY
A low surface expression level of human leukocyte antigen class I (HLA-I) ensures that the mesen-
chymal stem cells (MSCs) escape from the allogeneic recipients’ immunological surveillance. Here,
we discovered that both transcriptional and synthesis levels of HLA-I in MSCs increased continuously
after interferon (IFN)-g treatment, whereas interestingly, their surface HLA-I expression was downre-
gulated after reaching an HLA-I surface expression peak. Microarray data indicated that the post-
transcriptional process plays an important role in the downregulation of surfaceHLA-I. Further studies
identified that IFN-g-treated MSCs accelerated HLA-I endocytosis through a clathrin-independent
dynamin-dependent endocytosis pathway. Furthermore, cells that have self-downregulated surface
HLA-I expression elicit a weaker immune response than they previously could. Thus uncovering the
plasticity of MSCs in the regulation of HLA-I surface expression would reveal insights into the
membrane transportation events leading to the maintenance of low surface HLA-I expression,
providing more evidence for selecting and optimizing low-immunogenic MSCs to improve the thera-
peutic efficiency.
INTRODUCTION
Polymorphisms in human leukocyte antigen (HLA) class I genes can cause the rejection of stem cells or
tissue grafts in allogeneic recipients, which affects the safety and efficiency of therapies. Mesenchymal
stem cells (MSCs) have been widely considered and reported to have therapeutic function in various
degenerative and inflammatory diseases (Hosseini et al., 2018; Wang et al., 2016); so it is important to eval-
uate HLA-I expression on MSCs when considering about allogeneic MSC transplantation therapy.
Although MSCs can be isolated from multiple tissues including bone marrow, adipose, and umbilical
cord, only a very limited number of MSCs can be harvested from specific sources, generally requiring
several weeks of ex vivo expansion to reach the demanding therapeutic MSC dose. In addition, they
have been reported to exhibit large heterogeneity between different tissue sources and complicated
donors’ physical status in cell qualities following differentiation or immunomodulation abilities (Kim
et al., 2018; Kunimatsu et al., 2018; Yang et al., 2018). Therefore pluripotent stem cells, such as induced
pluripotent stem cells (iPSCs) and embryonic stem cells, were introduced as potential sources for MSCs
due to their capacity to differentiate into the MSC lineage. However, iPSCs have the potential risks of
chromosomal instability and oncogenic transformation associated with the application of viral vectors dur-
ing the reprogramming process (Okita et al., 2007; Yu et al., 2007). In addition, it raised a concern that the
reprogramming of iPSCs may be incomplete so that they still carry donor-specific characteristics, resulting
in iPSCs with variable gene expression or DNA methylation (Chin et al., 2009; Doi et al., 2009). Thus,
although allogeneic embryonic stem cells carry the risk of teratoma formation and face the challenge of
maintaining genetic stability during long-term culture (Hentze et al., 2007), these cells have recently
been proposed as an efficient source for MSC generation to provide high-quality ‘‘off-the-shelf’’ human
embryonic stem cell-derived MSC (hESC-MSC) products (Hematti, 2011). Hence, hESC-MSCs must abide
by a rigorous quality control system, evaluating their safety and immunogenicity during cell
transplantation.
The immunogenicity of MSCs remains poorly defined and controversial. The prevailing dogma considers
allogeneic MSCs as immune privileged or immune evasive. However, some studies showed the generation
of alloantibodies and immune rejection after allogeneic MSC transplantation.
Culture-expanded MSCs have been confirmed by expressing a low level of surface HLA-I, no HLA-II, and
costimulatory molecules including CD40, CD80, and CD86 (Klyushnenkova et al., 2005). Furthermore,66 iScience 15, 66–78, May 31, 2019 ª 2019 The Authors.
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https://doi.org/10.1016/j.isci.MSCs were reported to be capable of producing a variety of immunomodulatory cytokines such as pros-
taglandin E2, interleukin10, transforming growth factor b, HLA-G, 2,3-dioxygenase, and inducible
nitric oxide synthase, increasing the proportion of regulatory T cells and inhibiting the function of natural
killer (NK) cells and effector T cells (Aggarwal and Pittenger, 2005). Some studies illustrated that allogeneic
MSCs maintained low immunogenicity even after being immune challenged in vitro. In addition, when
compared with the injection of peripheral blood mononuclear cells in vivo, allogeneic MSC injection did
not elicit T cell proliferation and inflammatory cytokine secretion (Lee et al., 2014). Further evidence
from Zangi et al. showed that the MSCs (20 days) were able to survive longer when compared with
fibroblasts (10 days) in allogeneic host mice (Zangi et al., 2009). These results suggested that MSCs may
exhibit lower immunogenicity than other differentiated cells and that MSCs can regulate themselves, as
well as the environment, to maintain a hypo-immunogenic condition.
However, there also exist controversial reports regarding the immunogenicity of MSCs. It was reported that
MSCs became highly immunogenic after being transplanted into the host (Yang et al., 2017); previous
results indicated that allogeneic MSC injection stimulated the hosts’ T cell response, which threatened
MSC survival (Beggs et al., 2006). In addition, the ability of MSCs is often limited by the cell’s poor engraft-
ment rate, hindering their therapeutic efficiency, as well as the unknown route of MSC administration
(Gu et al., 2015). Reviews by Ankrum et al. and Berglund et al. provided a thorough discussion on the immu-
nogenicity of MSCs and insisted that it was worthwhile to consider MSC immunogenicity to improve the
efficiency and safety ofMSC therapies (Ankrumet al., 2014; Berglund et al., 2017). The rate of immune detec-
tion and elimination of allogeneicMSCs is dictated by the balance between a given cell’s relative expression
of immunogenic and immunosuppressive factors. Meanwhile, the cell cycle may also have an effect on the
stem cells’ immunogenicity. Agudo et al. have reported that the hair follicle stem cells (HFSCs) within the
telogen phase (quiescent state) can downregulate the antigen presentationmachinery to evade cellular im-
munity (Agudoet al., 2018). The cell state ofMSCs can alsobe regulated into aquiescent stateby altering the
culture medium or plate as previously reported (Moya et al., 2017; Rumman et al., 2018), but a publishedmi-
croarray data reported that quiescentMSCs induced a stronger immune response in contrast (GO:0006954,
PTSG2, IL10, IL1A, IL1B, CCR7) (Rumman et al., 2018). Thus it is still unknown whether it is beneficial to main-
tain MSCs in the quiescent phase to maintain low immunogenicity, especially low HLA-I expression. The
alterations of MSCs’ immunogenicity possibly depend on various factors including both the cell microenvi-
ronment and cell state. Therefore more studies need to be conducted to understand the details related to
MSCs’ immunogenicity, which could help improve the efficiency of MSC transplantation.
The major role of HLA-I is to act as an identifying card for all nucleated cells. In healthy individuals, all these
molecules are autologous to avoid being attacked by CD8+ T cells; however, when cells exhibit abnormal
characteristics (e.g., cancer cells, allotransplantation, and viral infections), they express aberrant or non-self
HLA-I molecules or antigens on their surface, rendering them to be targeted by CD8+ T cells for destruction
and elimination from the body to then be destroyed and eliminated from the body (Bjorkman et al., 1987).
Meanwhile, cells that have HLA-I defects will be targeted by NK cells (Kollnberger, 2016); therefore HLA-I
molecules are critical when considering allogeneic MSC transplantation.
The surface HLA-I expression level depends on both HLA-I presentation and HLA-I endocytosis. HLA-I
antigen processing and presenting machinery (APM) is relatively similar among different cell types and
is believed to contain several steps including protein breakdown, peptide transport, peptide trimming,
HLA-I assembling, and HLA-I-peptide complex exportation; however, the internalization components of
HLA-I vary between different cell types and status. In addition, because the HLA-I pathway gradually
evolves to improve its detection and elimination of abnormal cells, tumor cells and some virus-infected
cells have also coevolved and improved its cloaking mechanisms to avoid such detection. For example,
the abnormalities of antigen processing and presentation in HLA-I are discovered in many types of
cancers (Campoli et al., 2004), and a large majority of viruses have evolved ways to tamper with the APM
or internalize HLA-I from the cell membrane (Hewitt, 2003). Nearly every step in the assembly and trafficking
of HLA-I represents potential targets for ablating HLA-I expression on the cell surface. Nevertheless, it is
still unknown how MSCs regulate their HLA-I expression.
The majority of immunogenicity studies on MSCs were carried out in vitro, and it should be noted that
culture-expanded hMSCs typically express low levels of HLA-I on the surface, allowing them to evade
immune surveillance. MSCs have been verified to have therapeutic functions in many inflammatory
2019.04.011
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diseases such as osteoarthritis and autoimmune encephalitis; however, MSCs exposed to the inflammatory
cytokine, interferon (IFN)-g, can significantly express more HLA-I (Barrachina et al., 2016; Martini et al.,
2010). Therefore we investigated the expression level of HLA-I on hESC-MSCs and examined its underlying
regulatory mechanism, particularly in an inflamed microenvironment, hoping to better understand the
immunogenicity of MSCs and improve the efficiency of MSC therapy.RESULTS
MSCs Can Self-Downregulate Their HLA-I Surface Expression
In our previous study, characterization of MSC phenotype in the generated hESC-MSCs has been identified
(Wang et al., 2017); here we aimed to study the expression of HLA-I on hESC-MSCs in an inflamed niche.
IFN-g is one of the common inflammatory cytokines, secreted mainly from cytotoxic T lymphocytes. It has
been reported that IFN-g can upregulate HLA-I expression on cancer cells, leading to the activation of
tumor-specific immune response (Martini et al., 2010); however, it is still unclear whether IFN-g treatment
will have an effect on hESC-MSC HLA-I expression. In this study, we stimulated hESC-MSC with 100 U/mL
IFN-g for 0, 1, 2, and 3 days; qRT-PCR results demonstrated a continuous upregulation of polymorphic class
I molecule (HLA-A,HLA-B, andHLA-C) expression in hESC-MSCs following IFN-g stimulation (Figure 1A). In
addition, western blot results also illustrated a more prominent HLA-I band with longer stimulation time,
indicating that hESC-MSCs’ total HLA-I protein level expression was upregulated in the presence of
IFN-g, where the intensity also increases over time (Figures 1B and 1C). In contrast, data analyzed by
flow cytometry suggested a different expression outcome. Results illustrated that hESC-MSCs exhibited
a degree of plasticity to maintain homeostasis; at day 1, the surface HLA-I expression on hESC-MSCs
was first observed to be upregulated after IFN-g stimulation, and then the expression was automatically
downregulated (Figures 1D and 1E). When compared with hESC-MSCs, bone marrow MSCs exhibited
weaker HLA-I autoregulation ability as the downregulation of HLA-I initiated at day 2 after IFN-g
stimulation (Figures S1A and S1B); therefore the surface HLA-I auto-downregulation ability varies between
different sources of MSCs. Taken together, the presence of IFN-g upregulates HLA-I expression level in
hESC-MSCs; however, the cells are able to independently reverse the effect leading to the downregulation
of HLA-I surface expression in the later stage.Microarray Data Reveals the Transcriptional Changes in MSCs under IFN-g Treatment
To investigate hESC-MSCs’ underlying mechanism in the downregulation of HLA-I surface expression, we per-
formedmicroarrayanalysison IFN-g-stimulatedhESC-MSCsafter 0, 1, and3daysof stimulation (markedasDay0,
Day1, Day3); a total of 3,054 differentially expressed genes were significantly regulated in these three groups
(Figure 2A). According to the short time-series expression miner (STEM) analysis, the differential genes can be
classified into eight groups (Figure 2B), where we further focusedon the group (indicated as green background,
N= 312 genes) thatwas continuously upregulatedwith IFN-g treatment (Day3 >Day1>Day0) (Figure 2C). Gene
ontology enrichment analysis on this specific group was performed using DAVID; results indicated that these
genes were not only highly related with the immune response but also enriched in terms associated with vesicle
transportation and endocytosis pathway (Figure 2D, indicated as the red bar). Taken together, microarray data
indicated that the vesicle transportation and endocytosis pathway may play an important role in regulating the
hESC-MSCs’ surface HLA-I expression after IFN-g treatment.MSCs Accelerate the Endocytosis of Surface HLA-I
The HLA-I surface expression level is regulated by the balance between the endoplasmic reticulum
(ER)-Golgi-plasma membrane transportation rate and endocytosis transportation rate. Immunofluores-
cence was performed to determine the location of HLA-I in different organelles (ER, Golgi, endosome,
and lysosome) on samples of Day0, Day1, and Day3. Results illustrated that the co-localization of HLA-I
in ER was low both before and after IFN-g stimulation, whereas HLA-I molecules co-localized in the Golgi,
endosome, and lysosome were significantly upregulated after IFN-g treatment (Figure 3A). Consistently,
immunofluorescence intensity peaks of HLA-I (green line) were detected to be overlapped with Golgi,
endosome, and lysosome intensity peak (red line) separately, but not with the ER intensity peak (red
line) (Figure 3B). Quantitative analysis was also executed by measuring the co-localization rate with
Mander’s values ranging from 0 to 1, where bigger values indicate higher co-localization rate. Quantitative
results suggested that the HLA-I co-localized in the Golgi, endosome, and lysosome of hESC-MSCs were
all upregulated after IFN-g treatment; furthermore, the HLA-I in endosome was significantly upregulated at
Day3 when compared with Day1 (Figure 3C). Furthermore, flow cytometry was utilized to examine HLA-I68 iScience 15, 66–78, May 31, 2019
Figure 1. The HLA-I Expression of hESC-MSCs under IFN-g Treatment
(A) qRT-PCR expression analysis of HLA-I-related genes (including HLA-A, HLA-B, HLA-C, and B2M) on hESC-MSCs under
IFN-g treatment. RNA expression levels were normalized to the level of GAPDH expression. Data are shown asmeansG SEM.
(B) HLA-I expression on hESC-MSCs within IFN-g treatment for 0 day, 1 day, 2 days, and 3 days were compared by western
blot.
(C) The western blot results quantified analysis of HLA-I total expression level on hESC-MSCs within IFN-g treatment for
0 day, 1 day, 2 days, and 3 days. HLA-I expression levels were normalized to the level of GAPDH expression. Data are
shown as means G SEM.
(D) HLA-I surface expression on hESC-MSCs (red line) within IFN-g treatment for 0 day, 1 day, 2 days, and 3 days were
compared by flow cytometry analysis. Blue line demarcates isotype control.
(E) The flow cytometry results quantified analysis of HLA-I surface expression level on hESC-MSCs with IFN-g treatment for
0 day, 1 day, 2 days, and 3 days by mean fluorescence index. Data are shown as means G SEM.
See also Figures S1–S6.endocytosis rate in hESC-MSCs; results revealed that the HLA-I surface expression on hESC-MSCs was
significantly upregulated after IFN- g stimulation; however, it also showed faster endocytosis rate to down-
regulate surface HLA-I (Figure 3D). On the whole, these data demonstrated that hESC-MSCs upregulate
the plasma HLA-I endocytosis rate as a mechanism to reduce HLA-I surface expression.iScience 15, 66–78, May 31, 2019 69
Figure 2. The Transcription Microarray Analysis of hESC-MSCs under IFN-g Treatment
(A) The heatmap of differentially expressed genes between Day0, Day1, and Day3 hESC-MSCs.
(B) STEM analysis of all transcript levels differentially expressed genes between Day0, Day1, and Day3 hESC-MSCs.
‘‘n’’ represents the gene numbers of each profile.
(C) The STEM result of genes expression in the selected profile.
(D) Functional analysis of differentially expressed genes between Day0, Day1, and Day3 hESC-MSCs based on Gene
Ontology. Blue bars indicate immune-activation-related GO; red bars indicate transportation-related GO.MSCs Regulate HLA-I Endocytosis through the Clathrin-Independent Dynamin-Dependent
Pathway
To determine the exact endocytosis pathway responsible for the regulation of HLA-I surface expression, we
collected and applied several small molecules known to inhibit different endocytosis pathways (Figure 4A).
Selected inhibitors were then separately applied on IFN-g-stimulated hESC-MSCs where inhibitors marked
as S8047 (dynasore, dynamin inhibitor) and S1342 (genistein, clathrin-independent inhibitor) were shown to
lead to a significant increase in surface HLA-I expression; chloroquine, a lysosome inhibitor, also led to an
upregulation of HLA-1 surface expression, but not as significant as S8047 and S1342. Other endocytosis
and degeneration inhibitors showed very little or no effect on the cells’ HLA-I surface expression (Figure 4B).
To further validate the influence of S1342 and S8047 on hESC-MSCs’ HLA-I surface expression, cells were
treated with a concentration gradient of these inhibitors. Data revealed that the application of S8047 or70 iScience 15, 66–78, May 31, 2019
Figure 3. The Transportation of HLA-I in hESC-MSCs under IFN-g Treatment
(A) HLA-I subcellular location in different organelles (including ER Golgi, endosome, and lysosome) of Day0, Day1, and Day3 hESC-MSCs. Red indicates
organelles, green indicates HLA-I, and blue indicates DAPI. Scale bar, 50 mm.
(B) The immunofluorescence intensity analysis of HLA-I with different organelles in Day0, Day1, and Day3 hESC-MSCs (focused on the white line drawn on
Figure 3A). The red line indicates organelles, and the green line indicates HLA-I.
(C) Mander’s value analysis of co-localization rate of HLA-I and different organelles in Day1 and Day3 hESC-MSCs with the immunofluorescence results. n = 3
technical replicates. Data are shown as means G SEM.
(D) HLA-I endocytosis analysis on hESC-MSCs with or without IFN-g treatment by flow cytometry. The red line indicates IFN-g-treated hESC-MSCs, and the
blue line indicates IFN-g-untreated hESC-MSCs; dashed line indicates the endocytosis rate of surface HLA-I.S1342 at a higher dosage resulted in a stronger level of HLA-I surface expression (Figures 4C and 4D).
Furthermore, the combination of S8047 and S1342 was detected to further upregulate the HLA-I surface
expression when compared with a single inhibitor (Figure 4E). We also conducted a small interfering
RNA experiment to knockdown DNM2 and RHOA, respectively, and data showed that both of them upre-
gulate the surface HLA-I expression in the inflamed environment (Figures 4F and 4G). In conclusion, weiScience 15, 66–78, May 31, 2019 71
Figure 4. The Identification of the Selected Endocytosis Pathway for HLA-I in hESC-MSCs
(A) Summary of the selected inhibitors for different endocytosis pathways.
(B) The mean fluorescence index of HLA-I surface expression on hESC-MSCs with different inhibitor treatment was compared by flow cytometry analysis. The
black dashed line indicates the compared hESC-MSCs group with only IFN-g treatment. Data are shown as mean fluorescence index.
(C) The mean fluorescence index of HLA-I surface expression on IFN-g-treated hESC-MSCs with different dosage of S1342 treatment was compared by flow
cytometry analysis. Data are shown as means G SEM.
(D) The mean fluorescence index of HLA-I surface expression on IFN-g-treated hESC-MSCs with different dosage of S8047 treatment was compared by flow
cytometry analysis. Data are shown as means G SEM.
(E) The mean fluorescence index of HLA-I surface expression on IFN-g-treated hESC-MSCs with the combination of S1342 and S8047 treatment was
compared by flow cytometry analysis. Data are shown as means G SEM.
72 iScience 15, 66–78, May 31, 2019
Figure 4. Continued
(F) The mean fluorescence index of HLA-I surface expression on hESC-MSCs with different small interfering RNA (siRNA) transfection was compared by flow
cytometry analysis. Data are shown as means G SEM.
(G) The mean fluorescence index of HLA-I surface expression on IFN- g-treated hESC-MSCs with different siRNA transfection was compared by flow
cytometry analysis. Data are shown as means G SEM.suggest that hESC-MSCs regulate HLA-I endocytosis through the clathrin-independent and dynamin-
dependent pathways.The HLA-I Surface Expression Is Related with MSC Immunogenicity
To investigate whether the downregulation of surface HLA-I in hESC-MSCs is correlated with hESC-
MSC immunogenicity, we applied a one-way mixed lymphocytes reaction culture to evaluate the
immunogenicity of Day0, Day1, and Day3 hESC-MSCs. Allogeneic peripheral blood mononuclear cells
(PBMCs) were stained with Carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE) as responder
cells to reflect the proliferation rate. Results illustrated that hESC-MSCs in all groups were able to
induce allogenic PBMC proliferation to a certain extent; however, PBMCs stimulated with Day1
hESC-MSCs had fewer cells remaining in the unproliferated stage when compared with Day0 and
Day3 hESC-MSCs (Figure 5A). The corresponding quantitative result indicated that the proliferation
rate of PBMCs was the highest in the Day1 stimulation group, whereas that of the Day3 stimulation
group was lower but still a little stronger than that of the Day0 group (Figure 5B).
We further developed a humanized CD34+ mouse model to evaluate the immunogenicity of hESC-MSCs
in vivo, imitating the human immune system. Immunodeficient mice (NSG) were first irradiated and then
engrafted with human CD34+ hematopoietic stem cells to be reconstituted with human lymphocytes line-
ages. At 6 weeks post-engraftment, we subcutaneously injected the DiI-labeled hESC-MSCs into the
humanized mice; immunofluorescence staining results of hESC-MSCs revealed that these cells were able
to retain in the host mice for 2 weeks, but the intensity varied between different groups (Figure 5C).
Quantification analysis demonstrated that the immunofluorescence intensity of Day1 retained in the
humanized mice was especially weaker than that of Day0 and Day3 groups (Figure 5D). In addition, we
adopted the delayed-type hypersensitivity (DTH) test to assess T cell responses stimulated with different
hESC-MSCs. The humanized mice were first primed with Day0, Day1, or Day3 hESC-MSCs for 2 weeks
before the host mice were challenged with the same priming cells in footpads; thicker footpads signify a
stronger T cell response reaction. DTH results showed that all hESC-MSCs with different HLA-I expressions
were able to elicit allergic responses, whereas Day1 IFN-g-stimulated cells induced a stronger immune
response as reflected by the mice’s thicker footpads compared with those of the other groups (Figure 5E).
Consistently, histological H&E stainings revealed that the Day1-injected footpad exhibited more lympho-
cyte infiltration (Figure 5F). In summary, we compared the immunogenicity of Day0, Day1, and Day3
IFN-g-treated hESC-MSCs, and the results suggested that hESC-MSC immunogenicity is consistent with
HLA-I surface expression level.DISCUSSION
Taken together, these data demonstrated that hESC-MSCs exhibited plasticity in the regulation of surface
HLA-I expression under an inflamed environment. HLA-I molecules are expressed on all nucleated cells and
play an important role in allogeneic rejection through their presentation of peptide antigens to CD8+
T cells (Braciale, 1992), therefore a higher HLA-I expression on allogeneic cells will increase the risk of
rejection by the host. Our results indicated that HLA-I expression levels varied in different cell types,
with MSCs possessing a lower HLA-I surface expression when compared with somatic cells (Figures
S2A–S2D). Previous studies have reported that MSCs showed low immunogenicity, including low expres-
sion of major histocompatibility complex (MHC) class I (also named HLA-I in human) and no expression of
MHC class II and its co-stimulators CD40, CD80, and CD86 (Klyushnenkova et al., 2005). This phenomenon
suggests that hESC-MSCs may be a universal off-the-shelf cell for MSC therapeutic applications. However,
previous reports showed that the HLA-I expression level was also influenced by the different cell state and
different cellular environment. We compared the HLA-I expression between hESC-MSCs at a late passage
(slow cycle) and early passage (fast cycle) (Figure S3), where late-passage MSCs showed higher expression
of HLA-I. Moreover, we also induced hESC-MSCs into quiescence by serum deprivation (SD) for 48 h and
then compared their HLA-I surface expression with that of control hESC-MSCs in a standard culture con-
dition; the result illustrated that there was more HLA-I expressed on cells in the SD group (Figure S4). TheseiScience 15, 66–78, May 31, 2019 73
Figure 5. The Immunogenicity of hESC-MSCs with Day0, Day1, and Day3 hESC-MSCs
(A) PBMC proliferation rates with Day0, Day1, or Day3 hESC-MSC stimulation were compared by flow cytometry analysis. The FL1 subset indicates the
non-proliferated PBMCs; the FL1 subset-1, FL1 subset-2, and FL1 subset-3 indicate the proliferated PBMCs; the PBMCs in later subset proliferate more times
than the PBMCs in the former subset.
(B) PBMCproliferation rates with Day0, Day1, or Day3 hESC-MSC stimulation were quantified based on flow cytometry analysis. Data are shown asmeansG SEM.
(C) Humanized mice imaging with Day0, Day1, or Day3 hESC-MSC injection after 2 weeks.
(D) The quantification analysis of Day0, Day1, or Day3 hESC-MSC immunofluorescence retained in humanized mice. Data are shown as meansG SEM.
(E) The footpad thickness of humanized mice with Day0, Day1, or Day3 hESC-MSC challenge. Data are shown as means G SEM.
(F) The H&E staining of humanizedmice footpads with Day0, Day1, or Day3 hESC-MSC challenge. The black arrows indicate the infiltrated lymphocytes in the
footpad. Scale bar, 200 mm.
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results are consistent with the outcome reported by Rumman et al. (Rumman et al., 2018), suggesting
that MSCs express a higher surface level of HLA-I in the quiescent state. However, a study completed
by Agudo et al. (Agudo et al., 2018) reported that HFSCs downregulate MHC-I in their quiescent
state to evade immune surveillance. Thus MSCs and HFSCs had a different relationship between cell
immunogenicity and the quiescent cell state. We suppose that this may be caused by the different types
of stem cells: MSCs come from the mesenchyme, whereas HFSCs are from the epithelium. To MSCs
there were no benefits but disadvantages, to maintain the quiescent state to downregulate HLA-I
expression. When referring to the cellular microenvironment, IFN-g plays a major role in multiple
scenarios during immune activation; it is one of the most important pro-inflammatory cytokines produced
primarily by NK cells, CD4+T helper type 1 cells, cytotoxic CD8+T cells, and dendritic cells, macrophages,
and NK T cells (Eberl et al., 2015; Schroder et al., 2004), etc. Previous evidence indicated that IFN-g could
induce the immunosuppressive function of human MSCs, such as increasing the enzymatic activity of IDO1
or inhibiting CD4+/CD8+ T cell proliferation (Liotta et al., 2015; Sivanathan et al., 2014). Moreover, this
cytokine has also been reported to upregulate MHC-I transcription level, which increased tumor immuno-
genicity (Weber and Rosenberg, 1988); this avenue of tumor surveillance was determined to involve
recognition and elimination of tumor cells by cytotoxic T lymphocytes, recruited to the tumor mass via
IFN-g-induced chemokine signaling (Kunz et al., 1999). When considering MSCs, Chan et al. also found
that IFN-g markedly and instantly induced the expression of MHC-I in human bone marrow MSCs (Chan
et al., 2008). However, it is still unclear whether IFN-g treatment will have any impact on hESC-MSCs’
immunogenicity.
Consistent with tumor cells and bone marrow MSCs (Martini et al., 2010; Saric et al., 2002), our results
showed that IFN-g treatment was able to constantly upregulate both HLA-I transcription and total protein
levels. Interestingly, we observed that even though the HLA-I surface expression on hESC-MSCs was first
upregulated, the expression level then auto-downregulated in the later stage; therefore this suggested
that hESC-MSCs have the plasticity to maintain the level of HLA-I expression. However, recent reports
have stated that MSCs’ immunogenicity is influenced by multiple factors, including cell passages, donors’
age, physiological status, and tissue sources. Comparing with our data on bone-marrow-derived MSCs
(Figure S2A), we predicted that the autoregulating ability of MSCs’ HLA-I surface expression may also
be different between different sources of MSCs.
It has been reported that HIV-infected cells can downregulate the HLA-I surface expression by accelerating
the ARF6 endocytic pathway (Blagoveshchenskaya et al., 2002), as well as blocking the transportation of
HLA-I to the cell’s surface (Swann et al., 2001). However, the mechanism of hESC-MSCs in modulating
the downregulation of HLA-I surface expression is still unknown. Data obtained from our microarray
analysis revealed a hint that the vesicle transport and endocytosis pathway may play a part in mediating
the downregulation of HLA-I surface expression. To define which particular pathway was involved in the
downregulation of HLA-I expression, we determined the location where HLA-I was overexpressed in the
different subcellular fractions. We discovered a little amount of HLA-I co-localized within the ER, indicating
that hESC-MSCs do not avoid HLA-I translocating onto the cell surface by restricting the molecules to ER,
whereas plenty of HLA-I was found located in the Golgi, endosome, and lysosome. Moreover, the percent-
age of HLA-I located in the endosome and lysosome was found to be higher at Day3 when compared with
Day1, indicating that the downregulation of surface HLA-I is mainly due to the endocytosis and degrada-
tion of HLA-I. Our flow cytometry results confirmed that HLA-I surface expression on hESC-MSCs was
upregulated under IFN-g treatment; however, these cells exhibited faster surface HLA-I endocytosis rate
to maintain a low expression level of HLA-I.
Endocytosis, the process by which cells internalize macromolecules and surface proteins, involves several
distinct pathways (Elkin et al., 2016) including clathrin-mediated endocytosis, caveolae-mediated endocy-
tosis, and clathrin-independent endocytosis pathway. To identify the endocytosis pathway involved in
hESC-MSCs’ HLA-I expression regulation, we applied selective inhibitors of different pathways. When
compared with the non-treated group, results illustrated an increase in HLA-I surface expression when
inhibitors dynasore and genistin were applied; a higher dosage of these two inhibitors also resulted in
higher surface expression of HLA-I. Moreover, the combination of these two inhibitors also resulted in a
more efficient upregulation of HLA-I surface expression. The time series experiment implicated that
both dynasore and genistin have the ability to block the downregulation of HLA-I surface expression on
hESC-MSCs. These results all indicate that the HLA-I endocytosis in IFN-g-treated hESC-MSCs goes
through the clathrin-independent and dynamin-dependent endocytosis pathway.iScience 15, 66–78, May 31, 2019 75
HLA-I is one of the major molecules reflecting the graft cells’ immunogenicity; however, we were not sure if
the downregulation of HLA-I can exactly affect the cells’ immunogenicity. Mixed lymphocytes culture assay
has been considered as a traditional and superior method in predicting allograft rejection in vitro. We
co-cultured CFDA-SE-stained PBMCs with Day0, Day1, and Day3 hESC-MSCs separately and then tested
the proliferation rate of PBMCs. Flow cytometry results showed that Day1 hESC-MSCs induced the highest
stimulation index when compared with other groups (Day0 and Day3). Furthermore, we applied the DTH
model in humanized mice to evaluate cell-mediated immune responses associated with IFN-g-stimulated
hESC-MSCs stimulated at different time points. The mice challenged with Day1 hESC-MSCs showed a
more robust response in footpad swelling assays compared with those challenged with Day0 and Day3
hESC-MSCs. Meanwhile, histological staining results revealed that mice footpads challenged with Day1
hESC-MSCs had a significantly higher lymphocyte infiltration compared with those challenged with Day0
and Day3 hESC-MSCs. All these results indicated the importance of HLA-I surface expression in inducing
an allogeneic immune response, and the hESC-MSCs’ ability in regulating HLA-I expression can exactly
downregulate cell immunogenicity, and then reduce the risk of immune rejection.
In previous studies, researchers tried to use the gene editing method to modify HLA-I expression, either
targeted disruption of B2M gene in ESC to minimize the cells’ immunogenicity (Wang et al., 2015) or
replacement of the classical HLA-I with minimally polymorphic HLA-E molecules to escape allogeneic re-
sponses (Gornalusse et al., 2017). Here we discovered that hESC-MSCs obtained the ability to downregu-
late HLA-I surface expression naturally, even when stressed under pulsed IFN-g treatment (Figure S5).
Referring to a previous study, the MSCs showed enhanced T cell suppression when they were precondi-
tioned by incubating them with IFN-g for 48 h (Le Blanc et al., 2003). Thus maybe we can take advantage
of this special property by priming hESC-MSCs with an appropriate dosage of IFN-g for a specific time
duration to enhance their immune-suppressive capacity and also to maintain their low surface HLA-I
expression to evade immune surveillance. This may push forward the application of MSCs in clinical trials.
In summary, we revealed the ability of hESC-MSCs in auto-downregulating the surface HLA-I expression
with IFN-g treatment. This behavior has been manifested to leave the cell with low immunogenicity. This
discovery not only broadens our knowledge of hESC-MSCs but also provides a beneficial strategy to
minimize the risk of rejection.Limitations of the Study
This study focused on the plasticity of MSCs’ immunogenicity, which determines the cells’ survival in
the allogeneic host. IFN-g is an essential inflammatory cytokine, which has been identified to have the
ability to strengthen the MSCs’ immunomodulatory effect. So here we only focused on the IFN-g simulated
inflammatory environment, without considering other inflammatory cytokines or other specific disease
microenvironment.METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.SUPPLEMENTAL INFORMATION
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Transparent Methods 
Ethics Statement 
All experiments were approved by the institutional biosafety committee, institutional animal 
committee, and institutional review board of Zhejiang University. (No. ZJU2015-004) 
Cell culture and Differentiation 
The male H1 human ES cell line (ESC) was obtained from WiCell Corporation. Madison, WI, 
USA (http://www.wicell.org), and was maintained in the undifferentiated state in a feeder-free 
system. MSCs derived from ESC (hESC-MSCs) were directly differentiated, cultured, and 
identified as described in our previous study(Wang et al., 2017). In addition, the hESC-MSCs 
was normally cultured in standard conditions (L-DMEM within 10%FBS). However, for the 
serum deprivation experiment, the cells were seeded 10000 cells per cm2 and cultured under 
standard conditions over night. The following day, cells were rinsed with PBS and further 
cultured in L-DMEM with 5%FBS or L-DMEM without FBS for 48h, respectively. 
Cell stimulation 
The hESC-MSCs were stimulated with 100U/mL IFN-γ(PeproTech, Cat.300-02) in MSC 
culture media (L-DMEM+10%FBS) for 0 days, 1 day, 2 days, and 3 days, and then directly 
used for the following experiment(Figure S6A). The sample was marked as Day0, Day1, Day2, 
and Day3. As for the pulsative IFN-γ stimulation, the hESC-MSCs medium was transferred 
between medium within and without 100U/mL IFN-γ (Figure S6B). 
One-way mixed lymphocyte culture 
Human PBMCs were prepared from freshly collected, heparinized whole blood samples from 
donors through Ficoll-Paque PLUS (GE, Cat.17-1440-03). Briefly, whole human blood was 
diluted 1:2 with PBS and added into the Ficoll solution at 4:3(v/v) ratio. After centrifugation 
and washing, PBMCs were stained with CFDA SE (Beytime, Cat.C1031) to label the cell 
proliferation used as responder cells. The hESC-MSCs were then treated with 25µg/mL 
Mitomycin C used as stimulator cells. 104 stimulator cells and 105 responder cells were co-
cultured into a 96-well round-bottom plate (Corning) for 5 days. PBMCs proliferation was then 
analyzed with the fluorescence intensity by flow cytometry. 
Reconstitution of humanized mice 
The B-NDG mice (NOD-scid IL2 receptor gamma null mice) were purchased from Biocytogen 
Jiangsu Co., Ltd (Jiangsu, China) at 5 weeks of age. Human CD34+ cells were extracted from 
the donor blood through Ficoll-Paque PLUS (GE, Cat.17-1440-03) which is supplied by Bone 
Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang 
University, Hangzhou, China. Humanized mice were generated as previously 
described(Pearson et al., 2008). Briefly, the B-NDG mice were first treated with sublethal 
irradiation (1.8 Gy), then 5×105 human CD34+ cells were intravenously injected into the mice 
5 hours later. The CD34+ cells were isolated purified from human PBMCs using a MACS 
separation system with anti-human CD34+ antibody (Miltenyi Biotec, Cat. 130-046-702). After 
6 weeks, the mice were delivered to do the following experiment. 
Delayed-type hypersensitivity 
Humanized mice were injected subcutaneously with 200 µL 1×106 DiI (Beyotime, Cat.C1036) 
pre-stained hESC-MSCs (Day0, Day1, and Day3) at two sites on the back of the mice (priming). 
At 13 days after post-implantation, the mice were detected with immunofluorescence through 
In Vivo Imaging System (PE, IVIS Spectrum). 1×106 challenged hESC-MSCs (Day0, Day1, 
and Day3) in 20µL of PBS were injected into one hind footpad of humanized mice 
subcutaneously (challenge). Another 20µL of PBS were injected into the other hind footpad of 
humanized mice subcutaneously as the internal negative control. Evaluation of the responses 
was performed as previously described(Liu et al., 2012): [footpad swelling (mm)]=[footpad 
thickness of hESC-MSCs injected footpad (mm)]-[ footpad thickness of PBS injected footpad 
(mm)].  
H&E staining of the footpad 
At 24 hours post-challenge, humanized mice footpads of all groups were harvested and fixed 
in 4% paraformaldehyde. After decalcification in 10% EDTA at 4℃ for 4 weeks, footpads were 
cross-sectioned at the root of toes before paraffin embedding. Sections of 4µm thickness were 
made and stained with H&E. Images were captured under the slide scanning machine 
(Pannoramic MIDI, 3DHISTECH Ltd., Budapest, Hungray). 
Transfection of small interfering RNAs 
The siRNA sequences used in this study are as follows:siRNA-DNM2 (forward: 5’-
GCAACCUGGUGGACUCAUATT-3’, reverse: 5’-UAUGAGUCCACCAGGUUGCTT-3’); 
si-RHOA (forward: 5’-CCAGAAGUCAAGCAUUUCUTT-3’, reverse: 5’-
AGAAAUGCUUGACUUCUGGTT-3’); si-Negative Control (forward: 5’-
UUCUCCGAACGUGUCACGUTT-3’, reverse: 5’-ACGUGACACGUUCGGAGAATT-3’). 
Double-stranded siRNAs were synthesized by GenePharma. The reaction contained 100nM 
siRNAs, and transfections were performed using LipofectamineTM2000 Transfection Reagent 
(Invitrogen, Cat.11668019) . after 6 hours, the transfected cells were then refreshed with MSC 
medium. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Total RNA was isolated from hESC-MSCs by lysis in TRIzol (Takara, Shigo, Japan, Cat. 
#9109). Rever-Tra Ace qPCR RT Master Mix was applied during the reverse transcription 
process (Toyobo, Osaka, Japan, Cat. #FSQ-201). qRT-PCR was performed utilizing Brilliant 
SYBR Green QPCR Master Mix (Takara, Cat. # RR420A) with a LightCycler apparatus (480II, 
Roche, Mannheim, Germany). The amplification efficiencies of primer pairs were validated to 
enable quantitative comparison of gene expression. All primer sequences (Invitrogen) were 
designed using Primer 5.0 software (Table S1). Each qRT-PCR was performed three times on 
at least three different experimental replicates, and results were normalized to those obtained 
with the endogenous reference gene (GAPDH). 
Western blot assay  
Cellular protein was extracted with RIPA lysis buffer (Solarbio, Beijing, China, Cat. #R0010), 
and the total protein concentration was determined with a BCA Protein Assay Kit (Pierce, 
Rockford, IL, USA, Cat. #23225). The 20 µg extracted cellular protein was loaded on 10% 
(w/v) SDS-PAGE-denaturing gels. After electrophoresis, proteins were transferred to a 
polyvinylidene difluoride membrane and blocked in 5% (w/v) bovine serum albumin (BSA, 
Sangon Biotech, Shanghai, China, Cat. #9048-4b-8) for 1h at room temperature. The membrane 
was incubated overnight at 4 °C with mouse anti-HLA-I (1:1000; HLA-ABC, Novus, 
Cat.NB100-64775), or rabbit anti-GAPDH (1:1000; Beyotime, Cat. #AG019) antibody. After 
washing in Tris-buffered saline with Tween-20 (TBST), the horseradish peroxidase (HRP) 
secondary antibodies (HRP-labeled goat anti-mouse IgG (1:1000; Beyotime, Cat. #A0216) and 
goat anti-rabbit IgG antibody, peroxidase-conjugated (1:1000; EMD Millipore, Cat. #AP132P)) 
was diluted in 5% (w/v) BSA solution and incubated accordingly with the membrane for 1 h at 
room temperature (RT). The excessive secondary antibody was washed off by TBST, and a 
chemiluminescent signal was generated by the ECL Imaging Kit (Thermo Fisher Scientific, 
Waltham, MA, USA, Cat. #32209). 
Flow cytometry 
Cells were harvested by trypsinization (0.05% (w/v); Life Technologies, Cat. #15400-054) for 
2 min in a 37℃ incubator, and the cell pellet was re-suspended in PBS to a titer of 105/10 µL. 
The cell suspension was incubated with 10µL anti-HLA-I (1:30; HLA-ABC, Novus, 
Cat.NB100-64775) on ice for 30min. Cells were washed with PBS completely and incubated 
with 40µL anti-mouse Alexa Fluor 488(1:250; Donkey anti-Mouse IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488, Invitrogen, Cat. A-21202) on ice for 15min. 
Cells were washed with PBS completely and re-suspended in 1% (w/v) paraformaldehyde. 
Samples were run on the FC500MPL flow cytometer (Beckman Coulter, Brea, CA, USA) and 
the data were analyzed by FlowJo vX.0.7 software (FlowJo LLC, Ashland, OR, USA). 
RNA extraction and preparation 
Total RNA containing small RNA was extracted from IFN-γ-treated hESC-MSC samples using 
the Trizol reagent (Invitrogen) and purified with mirVana miRNA Isolation Kit (Ambion, 
Austin, TX, USA) according to manufacturer’s protocol. The purity and concentration of RNA 
were determined from OD260/280 readings using the spectrophotometer (NanoDrop ND-1000). 
RNA integrity was determined by 1% formaldehyde denaturing gel electrophoresis. Only RNA 
extracts with RNA integrity number values >6 were used for further study. 
Fabrication of DNA microarray 
CapitalBio Technology Human LncRNA Array v4 was designed with four identical arrays per 
slide (4 x 180K format), with each array containing probes interrogating about 41,000 human 
lncRNAs and about 34,000 human mRNAs. Those lncRNA and mRNA target sequences were 
merged from multiple databases, 23898 from GENCODE/ENSEMBL, 14353 from Human 
LincRNA Catalog(Orom et al., 2010), 7760 from RefSeq, 5627 from UCSC, 13701 from 
NRED (ncRNA Expression Database), 21488 from LNCipedia, 1038 from H-InvDB, 3019 
from LncRNAs-a (Enhancer-like), 1053 from Antisense lncRNA pipeline, 407 Hox ncRNAs, 
962 UCRs, and 848 from Chen Ruisheng lab (Institute of Biophysics, Chinese Academy of 
Science). Each RNA was detected by probes twice. The array also contains 4974 Agilent control 
probes.  
Microarray imaging and data analysis 
The lncRNA+mRNA array data were analyzed for data summarization, normalization, and 
quality control using the GeneSpring software V13.0 (Agilent). To select the differentially 
expressed genes, we used threshold values of ≥2 and ≤−2-fold change and a Benjamini-
Hochberg corrected p-value of 0.05. The data was Log2 transformed and median centered by 
genes using the Adjust Data function of CLUSTER 3.0 software, then further analyzed with 
hierarchical clustering with average linkage. Finally, we selected mRNAs with differentiated 
expression to perform short time series expression miner (STEM) analysis(Ernst and Bar-
Joseph, 2006). Genes classified in eight model profiles were further analyzed with DAVID.  
Flow cytometry analysis to assay endocytosis rate  
To detect the HLA-I endocytosis rate of hESC-MSCs, cells were harvested by trypsinization 
(0.05% (w/v); Life Technologies, Cat. #15400-054) for 2 min, and the cell pellet was re-
suspended in PBS to a titer of 106/100µL. The cell suspension was incubated with 100µL of 
HLA-ABC (1:25, Novus, Cat.NB100-64775) for 30min on ice. Cells were washed with PBS 
completely and resuspended in 50µL. The sample was divided into 5 parts: 0h, 1h, 2h, 5h, 7h. 
Cells were added in 1000µL cell medium and put back into the incubator to initiate endocytosis 
(37℃,5% CO2). At a certain time point, cells were put on the ice to stop the endocytosis process. 
Cell samples were harvested and centrifuged at 200× g, 5min, before resuspension in 40µL anti-
mouse Alexa Fluor 488(1:250; Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed 
Secondary Antibody, Alexa Fluor 488, Invitrogen, Cat. A-21202) on ice for 15min. Cells were 
then washed with PBS and re-suspended in 1% (w/v) paraformaldehyde. Samples were run on 
an FC500MPL flow cytometer (Beckman Coulter, Brea, CA, USA) and the data were analyzed 
by FlowJo vX.0.7 software (FlowJo LLC, Ashland, OR, USA). 
Statistical analysis 
All data were expressed as mean ± SEM unless otherwise stated. All experiments in vitro were 
repeated independently at least twice in addition to the triplicates applied in each experiment. 
Statistical results were analyzed and bar charts were constructed with GraphPad Prism version 
5.0 (GraphPad Software, San Diego, CA, USA). Statistical results were considered significant 
when the p-value was less than 0.05. Two-tailed Student’s t-test was used to compare two 
groups at the same time point. One-way ANOVA including the Tukey-Kramer post hoc test was 
used to compare multiple time point groups.  
Data and software available 
The accession number for microarray data reported in this paper is GEO Database: GSE122091. 
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Supplemental Figure Titles and Legends 
Figure S1. The HLA-I surface expression on hBMSCs under IFN-γ treatment, 
related to Figure 1.  
(A) HLA-I surface expression on hBMSCs (red line) within IFN-γ treatment for 0 day, 
1 day, 2 days and 3 days were compared by flow cytometry analysis. Blue line 
demarcates isotype control.  
(B) The flow cytometry results quantified analysis of HLA-I surface expression level 
on hBMSCs with IFN-γ treatment for 0 day, 1 day, 2 days and 3 days by mean 
fluorescence index. Data are shown as means±SEM. 
Figure S2. HLA-I levels are lower in hESC-MSCs than hFF, related to Figure 1.  
(A) qRT-PCR expression analysis of HLA-I related genes (include HLA-A, HLA-B, 
HLA-C, and B2M) on hESC-MSCs and hFF. RNA expression levels were normalized 
to the level of GAPDH expression. Data are shown as means±SEM. 
(B) HLA-I expression in hESC-MSCs and hFF were compared by western blotting. 
(C) HLA-I surface expression level on hESC-MSCs (red line) and hFF (blue line) were 
compared by flow cytometry analysis. Dashed lines demarcate isotype control. 
(D) The flow cytometry results quantified analysis of HLA-I surface expression level 
on hESC-MSCs (red bar) and hFF (blue bar) with mean fluorescence index. Data are 
shown as means±SEM. 
Figure S3. HLA-I levels are lower in hESC-MSCs at early passage than hESC-
MSCs at late passage, related to Figure 1.  
(A) hESC-MSCs growth curve at different passage(from passage0 to passage9). 
(B) The flow cytometry results quantified analysis of HLA-I surface expression level 
on passage3 hESC-MSCs (red bar) and passage8 hESC-MSCs(blue bar) with mean 
fluorescence index. Data are shown as means±SEM. 
Figure S4. HLA-I levels are higher in hESC-MSCs after the serum deprivation, 
related to Figure 1.  
(A) HLA-I surface expression level on hESC-MSCs under different concentration of 
FBS treatment for 48h was compared by flow cytometry analysis. The blue lines 
demarcate isotype control. 
(B) The flow cytometry results quantified analysis of HLA-I surface expression level 
on 10%FBS treated hESC-MSCs (red bar), 5%FBS treated hESC-MSCs(blue bar), and 
0%FBS treated hESC-MSCs(green bar) with mean fluorescence index. Data are shown 
as means±SEM. 
Figure S5. HLA-I levels in hESC-MSCs within pulsed IFN-γ treatment, related to 
Figure 1.  
(A) HLA-I surface expression level on hESC-MSCs under pulsed IFN-γ treatment was 
compared by flow cytometry analysis. The blue lines demarcate isotype control. 
(B) The flow cytometry results quantified analysis of HLA-I surface expression level 
on hESC-MSCs under pulsed IFN-γ treatment with mean fluorescence index. Data are 
shown as means±SEM. 
Figure S6. Schematic diagram of the collection about hESC-MSCs under IFN-γ 
treatment, related to Figure 1 and Figure S5.  
(A) The Schematic diagram of the collection about hESC-MSCs under continuous 
constant IFN-γ treatment.   
(B) The Schematic diagram of h the collection about hESC-MSCs under pulsed IFN-γ 
treatment.   
Table S1. The primers designed for qRT-PCR, related to Figure 1 and Figure S2. 
Gene Sequence(5’-3’) 
HLA-A-F TCCTTGGAGCTGTGATCACT 
HLA-A-R AAGGGCAGGAACAACTCTTG 
HLA-B-F ATTACATCGCCCTGAACGAG 
HLA-B-R ATCTCCGCAGGGTAGAAACC 
HLA-C-F TCCTGGTTGTCCTAGCTGTC 
HLA-C-R CAGGCTTTACAAGTGATGAG 
B2M-F GATGAGTATGCCTGCCGTGTG 
B2M-R CAATCCAAATGCGGCATCT 
GAPDH-F TGACGCTGGGGCTGGCATTG 
GAPDH-R GGCTGGTGGTCCAGGGGTCT 
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